Shareholders in Valeant Pharmaceuticals (TSX:VRX) used the company’s annual general meeting Tuesday as a forum to vent their gripes with the struggling drugmaker.
Some stockholders told CEO Joseph Papa that they were unhappy with Valeant’s low share price, insufficient response to negative media coverage and his predecessor’s lawsuit against the company seeking extra compensation.
Their frustration came after Papa said Valeant is making progress to stabilize itself after nearly two years of challenges, including a stock price that has plummeted from nearly $350 on the Toronto Stock Exchange in August 2015 to about $14 early Tuesday morning.
OBJ360 (Sponsored)
Give your home a stunning makeover—for 30 to 40 per cent less cost—with NorthCo Services
In the home renovation industry, companies don’t often see repeat clientele—but Ottawa’s NorthCo Services is a rare exception. “We have an upcoming project which will be the third one for
Paris, Tokyo, or Berlin, even if we don’t have centuries of urban legacy to build on. We have an official plan that, initially, sets out ambitious planning goals. The minutiae
Papa also said Valeant has made inroads to reduce its debt, adding that he doesn’t believe its current share price reflects the efforts it has made to turn itself around.
Still, he said a proposal to change the company’s name given the negative perception tarnishing it remains under consideration.
